Beranda › Kanker Payudara › Colorado › Denver
Uji klinis Kanker Payudara di Denver, CO
29 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Denver (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Vanguard Study: Testing a New Way to Screen for Cancer
Menerima pesertaSukarelawan sehat diterima
- Kaiser Permanente-Franklin, Denver
A Study of PHST001 in Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Rocky Mountain Cancer Center, Denver
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Menerima pesertaFase 3
- Rocky Mountain Cancer Centers, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- AdventHealth Porter, Denver
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Menerima pesertaFase 2
- Rocky Mountain Cancer Centers, Denver
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (Scri) At Health One, Denver
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Menerima pesertaFase 3
- UCHealth Cherry Creek Medical Center ( Site 0094), Denver
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Menerima pesertaFase 3
- Research Site, Denver
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Menerima pesertaFase 3
- UCHealth Cherry Creek Medical Center, Denver
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Menerima pesertaFase 2
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Menerima pesertaFase 3
- Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Menerima pesertaFase 3
- Clinical Trial Site, Denver
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- St. Joseph Hospital-Cancer Centers of Colorado, Denver
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Skin Cancer Institute, Englewood · 6 mi jauhnya
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute at HealthONE, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Menerima pesertaFase 2/3
- Rocky Mountain Cancer Centers, Denver
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Menerima pesertaFase 3
- Rocky Mountain Cancer Centers, Denver
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Denver
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Menerima pesertaFase 3
- Rocky Mountain Cancer Centers LLP, Denver
- Rocky Mountain Cancer Centers LLP, Englewood · 6 mi jauhnya
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Menerima pesertaFase 3
- UCHealth - Cherry Creek, Denver
- Rose Medical Center, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- dan 1 lainnya
The Immune System's Response to Young Women's Breast Cancer
Menerima pesertaStudi observasional
- Denver Health Hospital Authority, Denver
- UCHealth Cherry Creek Medcial Center, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Denver
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Menerima pesertaFase 1
- HealthONE, Denver
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Menerima pesertaStudi observasional
- Comprehensive Breast Care of Denver, Denver
Uji klinis Kanker Payudara di kota lain
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di Denver
- Kanker Metastatik29 studi
- Kanker Paru Non-Sel Kecil27 studi
- Mieloma Multipel27 studi
- Kanker Kolorektal23 studi
- Melanoma19 studi
- Kanker Prostat19 studi
- Kanker (semua jenis)18 studi
- Kanker Ovarium16 studi
- Kanker Paru16 studi
- Kanker Endometrium15 studi
- Limfoma Non-Hodgkin14 studi
- Kanker Pankreas13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.